BC
ALXN

Brookfield Corp’s Alexion Pharmaceuticals ALXN Stock Holding History

Brookfield Corp’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-97,000
Closed -$17.8M – 691
2021
Q2 		$17.8M Buy
97,000
+77,000
+385% +$13.2M 0.08% 95
2021
Q1 		$3.06M Sell
20,000
-9,000
-31% -$1.39M 0.01% 229
2020
Q4 		$4.53M Buy
+29,000
New +$3.73M 0.02% 174

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Brookfield Corp's ALXN Position: Q3 2021 in Review

Brookfield Corp sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 97,000 shares — an estimated $17.8M sold.

Brookfield Corp first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $17.8M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Brookfield Corp reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Brookfield Corp sold 97,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $17.8M.
  • Brookfield Corp first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Brookfield Corp's Alexion Pharmaceuticals position peaked at $17.8M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Brookfield Corp's 13F filing for Q3 2021, filed 16 Nov 2021.